Hypersensitivity Reaction Type Iii Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HYP072 MIFTS: 49	Hypersensitivity Reaction Type Iii Disease Categories: Cancer diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Hypersensitivity Reaction Type Iii Disease

MalaCards integrated aliases for Hypersensitivity Reaction Type Iii Disease:

Name: Hypersensitivity Reaction Type Iii Disease ¹² ¹⁵

Immune Complex Diseases ⁵⁶ ⁴⁵ ⁷⁴

Type Iii Hypersensitivity Reaction Disease ¹⁷

Immune Complex Disease ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:1557

MeSH ⁴⁵ D007105

EFO ¹⁷ EFO_1001222

UMLS ⁷⁴ C0020951

Sources

Summaries for Hypersensitivity Reaction Type Iii Disease

Disease Ontology : ¹² A hypersensitivity reaction disease that is characterized by the accumulation of antigen-antibody immune complexes, causing an inflammatory response and injury.

MalaCards based summary : Hypersensitivity Reaction Type Iii Disease, also known as immune complex diseases, is related to hypersensitivity vasculitis and membranoproliferative glomerulonephritis. An important gene associated with Hypersensitivity Reaction Type Iii Disease is HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Prednisone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Sources

Related Diseases for Hypersensitivity Reaction Type Iii Disease

Diseases in the Hypersensitivity Reaction Type Iv Disease family:

Hypersensitivity Reaction Type Iii Disease

Diseases related to Hypersensitivity Reaction Type Iii Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 270)

#	Related Disease	Score	Top Affiliating Genes
1	hypersensitivity vasculitis	31.2	C3 C4A CD79A CRP HSP90AA1 MEFV
2	membranoproliferative glomerulonephritis	30.7	ALB C3 C4A CD79A CFP ICAM1
3	complement deficiency	29.8	C3 C4A CFP
4	lupus erythematosus	29.3	C3 C4A C4B TNF
5	palindromic rheumatism	29.3	CRP MEFV TNF
6	pustulosis palmaris et plantaris	29.1	CD79A SELE TNF
7	typhoid fever	29.0	ALB CRP IL6 TNF
8	inflammatory bowel disease	28.6	CRP IL6 MPO TNF
9	myeloma, multiple	28.6	ALB CD79A CRP HSP90AA1 IL6 TNF
10	rheumatoid arthritis	28.3	CRP ICAM1 IL6 SELE TNF
11	synovitis	28.2	CRP ICAM1 IL6 SELE TNF
12	vasculitis	28.2	CRP ICAM1 MEFV MPO SELE TNF
13	glomerulonephritis	28.1	ALB C3 C4A C4B CD79A CFP
14	systemic lupus erythematosus	26.8	ALB C3 C4A C4B CD79A CRP
15	arthus reaction	11.3
16	c1q deficiency	10.9
17	complement component c1s deficiency	10.9
18	focal dermal hypoplasia	10.5	ALB CD79A
19	parotitis	10.5	ALB CD79A
20	root caries	10.5	ALB CD79A
21	arteriolosclerosis	10.4	C3 CD79A
22	abdominal tuberculosis	10.4	ALB CRP
23	pyuria	10.4	ALB CRP
24	gastrointestinal tuberculosis	10.4	ALB CRP
25	decubitus ulcer	10.4	ALB CRP
26	monoclonal paraproteinemia	10.4	HSP90AA1 MPO
27	epilepsy, familial temporal lobe, 2	10.4	C4A C4B
28	acute maxillary sinusitis	10.4	C3 CRP
29	acquired angioedema	10.4	C3 CRP
30	pasteurellosis	10.4	ALB MPO
31	juvenile dermatitis herpetiformis	10.4	C4A C4B
32	pleural empyema	10.4	CD79A CRP
33	chronic monocytic leukemia	10.4	C3 MPO
34	phototoxic dermatitis	10.4	C3 ICAM1
35	mononeuritis multiplex	10.3	CRP MPO
36	aortitis	10.3	CRP MPO
37	mediastinitis	10.3	CRP MPO
38	diffuse glomerulonephritis	10.3	ALB CFP
39	complement component 3 deficiency	10.3	C3 CFP
40	c3 glomerulopathy	10.3	C3 CFP
41	orthostatic proteinuria	10.3	ALB C3 HSP90AA1
42	euthyroid sick syndrome	10.3	ALB IL6
43	subacute bacterial endocarditis	10.2	CFP MPO
44	hymenolepiasis	10.2	ICAM1 SELE
45	mooren's ulcer	10.2	ICAM1 SELE
46	plummer's disease	10.2	ICAM1 SELE
47	pericardium disease	10.2	ALB CRP MEFV
48	immunodeficiency due to a classical component pathway complement deficiency	10.2	C4A C4B
49	subendocardial myocardial infarction	10.2	ICAM1 SELE
50	neutrophilia, hereditary	10.2	CRP IL6

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Iii Disease:

Sources

Symptoms & Phenotypes for Hypersensitivity Reaction Type Iii Disease

GenomeRNAi Phenotypes related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.1	ALB C3 C4A CD79A HSP90AA1 SELE

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Iii Disease:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.09	C3 C4B CFP CRP ICAM1 IL6
2	cellular	MP:0005384	10.06	ALB C3 CD79A HSP90AA1 ICAM1 IL6
3	homeostasis/metabolism	MP:0005376	10.03	ALB C3 C4B CD79A CFP CRP
4	hematopoietic system	MP:0005397	9.97	C3 C4B CD79A ICAM1 IL6 MEFV
5	immune system	MP:0005387	9.93	C3 C4B CD79A CFP CRP HSP90AA1
6	digestive/alimentary	MP:0005381	9.85	ALB C3 C4B ICAM1 IL6 TNF
7	liver/biliary system	MP:0005370	9.56	ALB C3 C4B CD79A IL6 MEFV
8	mortality/aging	MP:0010768	9.36	ALB C3 C4B CFP HSP90AA1 ICAM1

Sources

Drugs & Therapeutics for Hypersensitivity Reaction Type Iii Disease

Drugs for Hypersensitivity Reaction Type Iii Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Prednisone

Approved, Vet_approved

Phase 4,Phase 1,Phase 2,Not Applicable

53-03-2

5865

Prednisolone phosphate

Approved, Vet_approved

Phase 4,Phase 2,Not Applicable

302-25-0

Prednisolone

Approved, Vet_approved

Phase 4,Phase 2,Not Applicable

50-24-8

5755

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 2,Not Applicable

83-43-2

6741

Methylprednisolone hemisuccinate

Approved

Phase 4,Phase 2,Not Applicable

2921-57-5

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 2,Not Applicable

22916-47-8

4189

Tacrolimus

Approved, Investigational

Phase 4,Phase 2

104987-11-3

445643 439492 6473866

leucovorin

Approved

Phase 4,Phase 2

58-05-9

6006 143

Dapsone

Approved, Investigational

Phase 4,Phase 2

80-08-0

2955

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2

59-30-3

6037

Prednisolone hemisuccinate

Experimental

Phase 4,Phase 2,Not Applicable

2920-86-7

Anti-Inflammatory Agents

Phase 4,Phase 2,Phase 1,Not Applicable

Hormones

Phase 4,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 4,Phase 2,Phase 3,Not Applicable

Antineoplastic Agents, Hormonal

Phase 4,Phase 2,Phase 1,Not Applicable

Hormone Antagonists

Phase 4,Phase 2,Phase 1,Not Applicable

Immunologic Factors

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Calcineurin Inhibitors

Phase 4,Phase 2,Not Applicable

glucocorticoids

Phase 4,Phase 2,Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 2,Phase 1,Not Applicable

Protein Kinase Inhibitors

Phase 4,Phase 2,Phase 1,Not Applicable

Prednisolone acetate

Phase 4,Phase 2,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 2,Not Applicable

Anti-Infective Agents

Phase 4,Phase 2,Not Applicable

Autonomic Agents

Phase 4,Phase 2,Not Applicable

Antiemetics

Phase 4,Phase 2,Not Applicable

Methylprednisolone Acetate

Phase 4,Phase 2,Not Applicable

Protective Agents

Phase 4,Phase 2,Phase 1,Not Applicable

Antirheumatic Agents

Phase 4,Phase 2,Not Applicable

Gastrointestinal Agents

Phase 4,Phase 2,Not Applicable

Cyclosporins

Phase 4,Not Applicable

Neuroprotective Agents

Phase 4,Phase 2,Not Applicable

Antifungal Agents

Phase 4,Phase 2,Not Applicable

Dermatologic Agents

Phase 4,Not Applicable

Imatinib Mesylate

Phase 4,Phase 2,Phase 1,Not Applicable

220127-57-1

123596

Anti-Bacterial Agents

Phase 4,Phase 2,Not Applicable

Folic Acid Antagonists

Phase 4,Phase 2

Antiprotozoal Agents

Phase 4,Phase 2

Antiparasitic Agents

Phase 4,Phase 2

Vitamin B9

Phase 4,Phase 2

Folate

Phase 4,Phase 2

Vitamin B Complex

Phase 4,Phase 2

Antimalarials

Phase 4,Phase 2

Cladribine

Approved, Investigational

Phase 2, Phase 3,Phase 3

4291-63-8

20279

Omalizumab

Approved, Investigational

Phase 2, Phase 3

242138-07-4

Denosumab

Approved

Phase 3

615258-40-7

2-chloro-3'-deoxyadenosine

Phase 2, Phase 3,Phase 3

Histamine Antagonists

Phase 2, Phase 3,Phase 3

Respiratory System Agents

Phase 2, Phase 3

Anti-Asthmatic Agents

Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 89)

#	Name	Status	NCT ID	Phase	Drugs
1	Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis	Completed	NCT03222687	Phase 4	tacrolimus;prednisone
2	Imatinib in KIT-negative Systemic Mastocytosis	Completed	NCT01297777	Phase 4	Imatinib Mesylate
3	HSP-glomerulonephritis Trial: MP vs CyA	Completed	NCT00425724	Phase 4	Methylprednisolone pulses plus prednisone versus Cyclosporine A
4	Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome	Recruiting	NCT02550080	Phase 4	Dapsone
5	Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis	Unknown status	NCT01602939	Phase 2, Phase 3	Cladribine and pegylated interpheron alpha-2a
6	Study on Mastocytosis for Rupatadine Treatment	Completed	NCT01481909	Phase 2, Phase 3	Rupatadin
7	The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients	Completed	NCT01333293	Phase 2, Phase 3	injections
8	Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis	Completed	NCT00814073	Phase 3	Masitinib;Placebo
9	Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis	Recruiting	NCT03401060	Phase 3	Denosumab;Placebo
10	Midostaurin in Indolent Systemic Mastocytosis	Unknown status	NCT01920204	Phase 2	Midostaurin,
11	Evaluation of Response of Dasatinib to Treat Mastocytosis	Unknown status	NCT00979160	Phase 2	Dasatinib
12	Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura	Unknown status	NCT01104428	Phase 2	Placebo;"ziying" granules
13	A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines	Completed	NCT02956746	Phase 1, Phase 2
14	Treatment of Indolent Systemic Mastocytosis With PA101	Completed	NCT02478957	Phase 2	PA101;Placebo
15	Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia	Completed	NCT01807598	Phase 2	Brentuximab vedotin
16	Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation	Completed	NCT01266369	Phase 2	masitinib
17	Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis	Completed	NCT00831974	Phase 2	masitinib (AB1010);masitinib (AB1010)
18	Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia	Completed	NCT00782067	Phase 2	Midostaurin (PKC412)
19	Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis	Completed	NCT00769587	Phase 2	thalidomide
20	Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)	Completed	NCT00493129	Phase 2	Ontak (Denileukin Diftitox)
21	Efficacy and Safety of TF002 in Cutaneous Mastocytosis	Completed	NCT00457288	Phase 2	TF 002
22	Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis	Completed	NCT00449748	Phase 2	RAD001 (Everolimus)
23	Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)	Completed	NCT00255346	Phase 2	Dasatinib (BMS-354825)
24	Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia	Completed	NCT00233454	Phase 2	Midostaurin
25	Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	Completed	NCT00171912	Phase 2	imatinib mesylate
26	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis	Completed	NCT00132015	Phase 2	tanespimycin
27	A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers	Completed	NCT00109707	Phase 1, Phase 2	Nilotinib
28	Stem Cell Transplantation to Treat Systemic Mastocytosis	Completed	NCT00006413	Phase 2
29	Absorption of Corticosteroids in Children With Juvenile Dermatomyositis	Completed	NCT00004357	Phase 2	Methylprednisolone;Prednisolone
30	Flu Vaccine Response in Patients on Biologic Therapies	Recruiting	NCT03277703	Phase 2
31	Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis	Recruiting	NCT03770273	Phase 2
32	(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis	Recruiting	NCT03731260	Phase 2	Avapritinib;Placebo
33	(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis	Recruiting	NCT03580655	Phase 2	Avapritinib
34	Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment	Recruiting	NCT03591471	Phase 1, Phase 2	Glycosides Of Tripterygium Wilfordii Hook(GTW);Sulfotanshinone Sodium Injection;Chinese herbs based on syndrome differentiation;Prednisone Acetate Tablets;Benazepril Hydrochloride Tablets;Low Molecular Weight Heparin Calcium Injection;Dipyridamole Tab 25 MG;Chinese medicine placebo
35	A Randomized Multicenter Study for Isolated Skin Vasculitis	Recruiting	NCT02939573	Phase 2	Colchicine;Dapsone;Azathioprine
36	The Research of Standard Diagnosis and Treatment for Severe HSP in Children	Recruiting	NCT02540720	Phase 2	Dexamethasone;Gamma globulin
37	The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children	Recruiting	NCT02532790	Phase 2	Prednisone;ACEI
38	The Research of Standard Diagnosis and Treatment for HSPN in Children	Recruiting	NCT02532777	Phase 2	Prednisone;Cyclophosphamide(CTX);Mycophenolate mofetil(MMF);Leflunomide(LEF);Angiotensin-converting enzyme inhibitor(ACEI);Methylprednisolone
39	SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)	Recruiting	NCT02268253	Phase 1, Phase 2	SL-401
40	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies	Recruiting	NCT01384513	Phase 2	Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
41	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Not yet recruiting	NCT03739606	Phase 2
42	CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKEs) for High Risk Heme Malignancies	Not yet recruiting	NCT03214666	Phase 1, Phase 2	161533 Trike Phase I;161533 Trike Phase II
43	Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis	Terminated	NCT02415608	Phase 2	Ibrutinib
44	Cromoglicate in Mastocytosis	Terminated	NCT01701843	Phase 2	Cromoglicate;Placebo
45	Obatoclax for Systemic Mastocytosis	Terminated	NCT00918931	Phase 2	Obatoclax Mesylate
46	A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants	Completed	NCT02290340	Phase 1	Placebo;MEDI8897 10 mg;MEDI8897 25 mg;MEDI8897 50 mg
47	Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults	Completed	NCT02255760	Phase 1	MEDI3902 - Dose 1;MEDI3902 - Dose 2;MEDI3902 - Dose 3;MEDI3902 - Dose 4
48	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002	Completed	NCT02808793	Phase 1	AK002
49	Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies	Recruiting	NCT02561988	Phase 1	Avapritinib
50	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	Recruiting	NCT02571036	Phase 1	DCC-2618

Search NIH Clinical Center for Hypersensitivity Reaction Type Iii Disease

Cochrane evidence based reviews: immune complex diseases

Sources

Genetic Tests for Hypersensitivity Reaction Type Iii Disease

Sources

Anatomical Context for Hypersensitivity Reaction Type Iii Disease

MalaCards organs/tissues related to Hypersensitivity Reaction Type Iii Disease:

⁴²

Skin, Bone, Bone Marrow, Neutrophil, Testes, T Cells, Myeloid

Sources

Publications for Hypersensitivity Reaction Type Iii Disease

Articles related to Hypersensitivity Reaction Type Iii Disease:

(show all 32)

#	Title	Authors	Year
1	Rheumatoid arthritis and systemic lupus erythematosus as immune complex diseases. ( 19852746 )	Weissmann G	2009
2	A full complement of receptors in immune complex diseases. ( 12488423 )	Ravetch JV	2002
3	[Therapeutic plasmapheresis in immune complex diseases]. ( 7985137 )	Movshev B.E....Petrova V.I.	1994
4	Effectiveness of nafamostat mesilate on glomerulonephritis in immune-complex diseases. ( 8098488 )	Miyata T...Maeda K	1993
5	Immune complex diseases. ( 8424984 )	Virella G	1993
6	Immune complex diseases. ( 2151123 )	Virella G	1990
7	Cationic polyelectrolytes: a new look at their possible roles as opsonins, as stimulators of respiratory burst in leukocytes, in bacteriolysis, and as modulators of immune-complex diseases (a review hypothesis). ( 2961690 )	Ginsburg I	1987
8	Complement and immune complex diseases. ( 2944500 )	Webb J...Whaley K	1986
9	Detection of complement activation in immune complex diseases: six methods compared. ( 2946496 )	Sun T...Stagias J	1986
10	Neutrophil-mediated cellular cytotoxicity triggered by immobilized aggregated IgG: an in vitro model of cell injury during immune complex diseases. ( 6096393 )	Dallegri F...Sacchetti C	1984
11	Treatment of immune complex diseases. ( 6239985 )	Kater L	1984
12	Complement-mediated inhibition of immune precipitation in patients with immune complex diseases. ( 6220848 )	Naama JK...Whaley K	1983
13	Plasma exchange and immune complex diseases: the predictability of immune complexes removal to clinical response. ( 6460383 )	Valbonesi M...Cantarella S	1982
14	Factors influencing the development of immune-complex diseases. ( 6461275 )	Lamers MC	1981
15	Plasmapheresis in patients with leukaemia, multiple myeloma and immune complex diseases. ( 6454615 )	M?d A...Holl?n SR	1981
16	The effect of plasma exchange on the in vitro monocyte function of patients with immune complex diseases. ( 6459197 )	Steven MM...Wright R	1981
17	Coexisting immune complex diseases in atopy. ( 6449893 )	Rebhun J	1980
18	Is autoimmunity a common denominator in immune complex diseases? ( 6101634 )	Lewis EJ...Roberts JL	1980
19	Pathopysiological aspects of immune complex diseases. Part II. Phagocytosis, exocytosis, and pathogenic depositions. ( 6447230 )	Sedlacek HH	1980
20	Plasmapheresis in patients with leukaemia, multiple myeloma and immune complex diseases. ( 6449819 )	M?d A...Holl?n SR	1980
21	Biochemical aspects of immune complex formation and immune complex diseases. ( 6451188 )	Steensgaard J...Johansen AS	1980
22	Pathophysiologicl aspects of immune complex diseases part i. interaction with plasma enzyme systems, cell membranes and the immune response. ( 7392533 )	Sedlacek HH	1980
23	A nephelometric study of the reaction of monoclonal rheumatoid factor with heat aggregated gamma globulin and sera from patients with immune complex diseases. ( 92379 )	Roberts-Thomson PJ...Bradley J	1979
24	Serum complement profile in human leprosy and its comparison with immune complex diseases. ( 147246 )	Saha K...Chakraborty AK	1977
25	Editorial: Are the inflammatory bowel diseases immune complex diseases? ( 128486 )	Thayer WR	1976
26	Proceedings: Models of immune complex diseases and the role of antibody affinity. ( 129487 )	Steward MW	1976
27	Canine immune complex diseases. ( 136591 )	Plechner AJ	1976
28	Immunity. II. Immune complex diseases. ( 4277523 )	McNutt DR	1974
29	Immune complex diseases. ( 4264709 )	Dixon FJ	1972
30	Virus-associated immunopathology: animal models and implications for human disease. 1. Effects of viruses on the immune system, immune-complex diseases, and antibody-mediated immunologic injury. ( 4404992 )	Allison AC...Torrigiani G	1972
31	Immune complex diseases. I. Pathological changes in the kidneys of BALB-c mice neonatally infected with Moloney leukaemogenic and murine sarcoma viruses. ( 4333814 )	Branca M...Hirsch MS	1971
32	Immune complex diseases. ( 4398333 )	Cream JJ	1971

Sources

Genes for Hypersensitivity Reaction Type Iii Disease

Genes related to Hypersensitivity Reaction Type Iii Disease (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	HSP90AA1	Heat Shock Protein 90 Alpha Family Class A Member 1	Protein Coding	16.56	DISEASES inferred ¹⁵
2	MEFV	MEFV Innate Immuity Regulator, Pyrin	Protein Coding	16.43	DISEASES inferred ¹⁵
3	ALB	Albumin	Protein Coding	16.15	DISEASES inferred ¹⁵
4	C3	Complement C3	Protein Coding	16.07	DISEASES inferred ¹⁵
5	CD79A	CD79a Molecule	Protein Coding	15.87	Novoseek inferred ⁵⁶	12432435 8518104
6	C4A	Complement C4A (Rodgers Blood Group)	Protein Coding	15.62	DISEASES inferred ¹⁵
7	C4B	Complement C4B (Chido Blood Group)	Protein Coding	15.57	DISEASES inferred ¹⁵
8	CRP	C-Reactive Protein	Protein Coding	15.4	DISEASES inferred ¹⁵
9	MPO	Myeloperoxidase	Protein Coding	15.15	DISEASES inferred ¹⁵
10	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	15.14	DISEASES inferred ¹⁵
11	SELE	Selectin E	Protein Coding	15.13	DISEASES inferred ¹⁵
12	IL6	Interleukin 6	Protein Coding	15.02	DISEASES inferred ¹⁵
13	TNF	Tumor Necrosis Factor	Protein Coding	15.01	DISEASES inferred ¹⁵
14	CFP	Complement Factor Properdin	Protein Coding	14.97	DISEASES inferred ¹⁵

Sources

Variations for Hypersensitivity Reaction Type Iii Disease

Sources

Expression for Hypersensitivity Reaction Type Iii Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Iii Disease.

Sources

Pathways for Hypersensitivity Reaction Type Iii Disease

Pathways related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

(show all 30)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁷ Show member pathways Immune System ⁶⁷ Neutrophil degranulation ⁶⁷	13.69	C3 C4A C4B CD79A CFP CRP
2	Toll-like Receptor Signaling Pathway ³⁸ ¹ Show member pathways Chagas disease (American trypanosomiasis) ³⁸ Epstein-Barr virus infection ³⁸ Hepatitis B ³⁸ Hepatitis C ³⁸ NOD-like Receptor Signaling Pathways ⁶⁶ Regulation of toll-like receptor signaling pathway ¹	13.06	C3 HSP90AA1 IL6 MEFV TNF
3	Allograft rejection ¹ ³⁸ Show member pathways Antigen processing and presentation ³⁸ Asthma ³⁸ Autoimmune thyroid disease ³⁸ CTL Mediated Apoptosis ⁶⁵ Graft-versus-host disease ³⁸ Intestinal immune network for IgA production ³⁸ THC Differentiation Pathway ⁶⁵ Type I diabetes mellitus ³⁸ Viral myocarditis ³⁸	12.79	C3 C4A HSP90AA1 ICAM1 IL6 TNF
4	Influenza A ³⁸ Show member pathways Measles ³⁸	12.5	C3 CFP ICAM1 IL6 TNF
5	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	12.11	C4A C4B IL6 TNF
6	Creation of C4 and C2 activators ⁶⁷ Show member pathways Alternative complement activation ⁶⁷ Classical antibody-mediated complement activation ⁶⁷ Complement cascade ⁶⁷ Ficolins bind to repetitive carbohydrate structures on the target cell surface ⁶⁷ Initial triggering of complement ⁶⁷ Lectin pathway of complement activation ⁶⁷ Terminal pathway of complement ⁶⁷	12.05	C3 C4A C4B CRP
7	Fluid shear stress and atherosclerosis ³⁸	12.03	HSP90AA1 ICAM1 SELE TNF
8	Complement and coagulation cascades ³⁸ ¹	11.96	C3 C4A C4B
9	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁶	11.93	CD79A IL6 MPO TNF
10	Interleukin-4 and 13 signaling ⁶⁷	11.92	HSP90AA1 ICAM1 IL6 TNF
11	Spinal Cord Injury ¹	11.89	ICAM1 IL6 TNF
12	TNF signaling pathway ³⁸	11.89	ICAM1 IL6 SELE TNF
13	Complement Pathway ⁶⁵ Show member pathways Alternative Complement Pathway ⁶⁵ Classical Complement Pathway ⁶⁵ Complement Activation ¹ Complement Activation Pathways ⁶⁸ Lectin Induced Complement Pathway ⁶⁵	11.86	C3 C4A C4B CFP
14	AGE-RAGE signaling pathway in diabetic complications ³⁸	11.83	ICAM1 IL6 SELE TNF
15	Immune response Lectin induced complement pathway ²³ Show member pathways Activation of C3 and C5 ⁶⁷ Immune response Alternative complement pathway ²³ Immune response Classical complement pathway ²³ Regulation of Complement cascade ⁶⁷	11.78	C3 C4A C4B CFP CRP
16	Selenium Micronutrient Network ¹ Show member pathways Folate Metabolism ¹ Metabolism of ingested MeSeO2H into MeSeH ⁶⁷ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	11.77	ALB CRP ICAM1 IL6 MPO TNF
17	Rheumatoid arthritis ³⁸	11.76	ICAM1 IL6 TNF
18	Glucocorticoid receptor regulatory network ¹	11.71	HSP90AA1 ICAM1 IL6 SELE
19	Staphylococcus aureus infection ³⁸	11.57	C3 C4A C4B ICAM1
20	Photodynamic therapy-induced NF-kB survival signaling ¹ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²³	11.56	ICAM1 IL6 SELE TNF
21	Legionellosis ³⁸	11.53	C3 IL6 TNF
22	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.49	HSP90AA1 IL6 TNF
23	Interleukin-10 signaling ⁶⁷	11.47	ICAM1 IL6 TNF
24	Malaria ³⁸	11.4	ICAM1 IL6 SELE TNF
25	amb2 Integrin signaling ¹	11.35	ICAM1 IL6 MPO TNF
26	African trypanosomiasis ³⁸	11.02	ICAM1 IL6 SELE TNF
27	Transcription factor regulation in adipogenesis ¹	10.99	IL6 TNF
28	Overview of nanoparticle effects ¹	10.97	CRP IL6 TNF
29	Pertussis ³⁸	10.9	C3 C4A C4B IL6 TNF
30	LDL Oxidation in Atherogenesis ⁶⁵	10.86	ICAM1 MPO TNF

Sources

GO Terms for Hypersensitivity Reaction Type Iii Disease

Cellular components related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular exosome	GO:0070062	9.91	ALB C3 C4A C4B HSP90AA1 ICAM1
2	extracellular region	GO:0005576	9.65	ALB C3 C4A C4B CFP CRP
3	membrane raft	GO:0045121	9.62	CD79A ICAM1 SELE TNF
4	blood microparticle	GO:0072562	9.56	ALB C3 C4A C4B
5	endoplasmic reticulum lumen	GO:0005788	9.55	ALB C3 C4A CFP IL6
6	extracellular space	GO:0005615	9.36	ALB C3 C4A C4B CFP CRP

Biological processes related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

(show all 24)

#	Name	GO ID	Score	Top Affiliating Genes
1	immune system process	GO:0002376	9.92	C3 C4A C4B CD79A MEFV
2	post-translational protein modification	GO:0043687	9.88	ALB C3 C4A IL6
3	cytokine-mediated signaling pathway	GO:0019221	9.85	HSP90AA1 ICAM1 IL6 TNF
4	innate immune response	GO:0045087	9.8	C3 C4A C4B CFP CRP MEFV
5	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.79	ICAM1 IL6 TNF
6	negative regulation of endopeptidase activity	GO:0010951	9.79	C3 C4A C4B
7	cellular protein metabolic process	GO:0044267	9.76	ALB C3 C4A IL6
8	defense response to Gram-positive bacterium	GO:0050830	9.73	CRP IL6 TNF
9	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.71	HSP90AA1 IL6 TNF
10	complement activation, classical pathway	GO:0006958	9.71	C3 C4A C4B CRP
11	regulation of complement activation	GO:0030449	9.67	C3 C4A C4B CFP
12	positive regulation of chemokine production	GO:0032722	9.61	IL6 TNF
13	positive regulation of nitric oxide biosynthetic process	GO:0045429	9.61	HSP90AA1 ICAM1 TNF
14	leukocyte tethering or rolling	GO:0050901	9.6	SELE TNF
15	positive regulation of glial cell proliferation	GO:0060252	9.59	IL6 TNF
16	negative regulation of growth of symbiont in host	GO:0044130	9.58	MPO TNF
17	complement activation, alternative pathway	GO:0006957	9.57	C3 CFP
18	complement activation	GO:0006956	9.56	C3 C4A C4B CFP
19	opsonization	GO:0008228	9.51	C4B CRP
20	positive regulation of leukocyte adhesion to vascular endothelial cell	GO:1904996	9.49	ICAM1 TNF
21	positive regulation of neuroinflammatory response	GO:0150078	9.48	IL6 TNF
22	negative regulation of lipid storage	GO:0010888	9.33	CRP IL6 TNF
23	inflammatory response	GO:0006954	9.23	C3 C4A C4B CRP IL6 MEFV
24	positive regulation of apoptotic cell clearance	GO:2000427	9.13	C3 C4A C4B

Molecular functions related to Hypersensitivity Reaction Type Iii Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	serine-type endopeptidase activity	GO:0004252	9.46	C3 C4A C4B CFP
2	complement component C1q binding	GO:0001849	8.96	C4A CRP
3	endopeptidase inhibitor activity	GO:0004866	8.8	C3 C4A C4B

Sources

Sources for Hypersensitivity Reaction Type Iii Disease

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia